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ABSTRACT
Pneumococcal disease (including community-acquired
pneumonia and invasive pneumococcal disease) poses a
burden to the community all year round, especially in
those with chronic underlying conditions. Individuals
with COPD, asthma or who smoke, and those with
chronic heart disease or diabetes mellitus have been
shown to be at increased risk of pneumococcal disease
compared with those without these risk factors. These
conditions, and smoking, can also adversely affect
patient outcomes, including short-term and long-term
mortality rates, following pneumonia. Community-
acquired pneumonia, and in particular pneumococcal
pneumonia, is associated with a signiﬁcant economic
burden, especially in those who are hospitalised, and
also has an impact on a patient’s quality of life.
Therefore, physicians should target individuals with
COPD, asthma, heart disease or diabetes mellitus, and
those who smoke, for pneumococcal vaccination at the
earliest opportunity at any time of the year.
INTRODUCTION
Pneumococcal disease in adults, including
community-acquired pneumonia (CAP) and inva-
sive pneumococcal disease (IPD), is a global
problem,1–4 especially in individuals with chronic
diseases such as COPD, diabetes mellitus and
chronic heart disease (CHD). Due to the chronic
nature of these conditions, affected individuals are
at risk of CAP and IPD all year round, not only
during the winter, unlike seasonal inﬂuenza.5
This review addresses two key questions concern-
ing the burden of pneumococcal disease to help
physicians target vaccination to appropriate indivi-
duals: who is at increased risk of CAP and IPD;
and what are the effects of risk factors on the sever-
ity and prognosis of pneumococcal disease? It also
highlights the economic burden of pneumococcal
disease, the impact of pneumococcal disease on
underlying comorbidities, and the importance of
timely vaccination. We have focused primarily on
COPD, asthma, smoking, diabetes and/or CHD as
these are common risk factors for pneumococcal
disease in primary practice. There are, however,
many other risk factors.6–8 As Streptococcus pneu-
moniae is the most frequent cause of CAP irrespect-
ive of age and comorbidity,1 9 information has been
provided on all-cause pneumonia (ie, CAP) and
pneumococcal pneumonia.
SEARCH METHODOLOGY
A broad search strategy was used to ﬁnd English
language publications in human adults indexed on
PubMed (2004–November 2014). Relevant publi-
cations were manually selected from the following
searches: pneumonia AND risk factor, CHD AND
pneumonia, diabetes AND pneumonia, lung disease
AND pneumonia, asthma AND pneumonia, COPD
AND pneumonia, tobacco OR smoking AND
pneumonia, and economic data AND pneumonia.
Data comparing the risk of pneumococcal disease
in adults with the above risk factors versus those
without risk factors were tabulated (excluding pub-
lications prior to 2008 or with data prior to 2000),
and these data used to discuss the risk of pneumo-
coccal disease in individuals with these risk factors.
POPULATIONS AT RISK OF PNEUMOCOCCAL
DISEASE
Individuals with COPD, asthma or who smoke,
and those with CHD or diabetes mellitus, are at
increased risk of pneumococcal disease (CAP and
IPD) compared with those without these risk
factors.7 10–15 Similar rate ratios for all-cause pneu-
monia (CAP), pneumococcal pneumonia and IPD
have been reported in individuals with comorbid-
ities (versus those without comorbidities).7
Chronic respiratory diseases
Patients with chronic respiratory disease (COPD,
chronic bronchitis and/or asthma) are at a higher risk
of CAP and IPD than individuals without these
comorbidities with fold increases of between 1.3 and
13.5 for CAP and 1.3 and 16.8 for IPD (OR; table 1;
see online supplementary table S1).7 8 12 13 15–26
Risk of CAP varies with condition and age, with
older individuals (≥65 years of age) with COPD
being at especially high risk.19–21 Among indivi-
duals with COPD, those aged 65–79 or ≥80 years
have been shown to have an increasingly higher
risk of CAP than those aged 45–65 years.21 Having
COPD, and greater age, lack of pneumococcal vac-
cination, and corticosteroid therapy have been
identiﬁed as independent factors for recurrent CAP
in adults.17
The severity of the underlying respiratory condi-
tion affects the risk of CAP.15 19 21 Individuals aged
≥65 years who have mild lung disease (not requir-
ing medication or oxygen) have been shown to be
twice as likely to have CAP as those without lung
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disease, whereas those with severe lung disease (requiring
oxygen) are eight times more likely to have CAP.19 Similarly,
moderate and severe lung disease (percentage predicted FEV1:
50–80% and <50%, respectively) have been identiﬁed as signiﬁ-
cant risk factors for CAP in individuals aged ≥65 years com-
pared with normal or mild lung disease (HR: 1.78 and 2.90,
respectively).15 Moderate COPD exacerbation and hospitalisa-
tion due to severe COPD exacerbation have also been identiﬁed
as independent risk factors for CAP in patients with COPD
aged ≥45 years.21
Use of inhaled corticosteroids, a frequent medication in
COPD, has been associated with an increased risk of CAP.16 18
In a case–control study conducted in hospitalised patients aged
≥65 years, use of inhaled corticosteroids was found to be an
independent risk factor for CAP (adjusted OR: 2.89).18 Inhaled
corticosteroids were also associated with CAP in another case–
control study involving individuals over 14 years of age (OR:
3.09).16 In both these studies, the risk of CAP was higher in
those receiving inhaled corticosteroids than in those receiving
β2-adrenergic agonists.
16 18 Furthermore, the use of inhalers,
especially with a chamber spacer, was identiﬁed as an independ-
ent risk factor for CAP (multivariate OR: 1.57),16 which may be
due to contamination of the inhaler or deep inhalation of pres-
surised aerosols aiding penetration of microorganisms into the
bronchial tree.
Another study found that inhaled corticosteroids increased
the risk of CAP in patients with COPD, whereas inhaled antic-
holinergics increased the risk of CAP in patients with asthma.27
Inhaled β2-adrenergic agonists, however, did not appear to
affect the risk of CAP.27 The authors of this study concluded
that these associations may not be causal but reﬂect the severity
of the underlying conditions. A recent Cochrane review con-
cluded that the inhaled corticosteroids budesonide and ﬂutica-
sone, administered alone or in combination with a long-acting
β2 agonist, increase the risk of pneumonia requiring hospitalisa-
tion in patients with COPD, although they do not signiﬁcantly
affect mortality compared with controls.28
Within a patient population with underlying lung diseases,
patients with COPD have been found to have a higher risk of
IPD than those with asthma, regardless of age (fourfold vs
twofold increased risk of IPD).13 The increased risk of IPD in
individuals with COPD may be due to reduced innate defence
mechanisms in the airways, smoking and/or use of
corticosteroids.13
Table 1 Overview of risk factors associated with community-acquired pneumonia and pneumococcal disease
Risk factor
Cohort studies Case-control studies
Number of cohorts* Risk range† Number of cohorts* Risk range†
Community-acquired pneumonia
Chronic respiratory diseases 8‡ OR: 1.5
HR: 2.9
Rate ratio: 3.8–8.6
15§ OR: 1.3–13.5
RR: 1.6–2.8
HR: 1.2
Current smoking status 4 HR: 1.1
Rate ratio: 3.3–4.0
6 OR: 1.0–2.3
HR: 2.0
RR: 1.5
Diabetes mellitus 7 HR: 1.0–1.9
Rate ratio: 1.6–3.1
9 OR: 1.0–1.4
HR: 1.1
RR: 1.2–1.3
Chronic heart disease 6 HR: 1.5–3.1
Rate ratio: 3.8–4.9
17 OR: 1.0–3.3
HR: 1.3
RR: 1.3–2.6
Pneumococcal pneumonia
Chronic respiratory diseases 6¶ Rate ratio: 3.7–9.8 0 –
Current smoking status 3 Rate ratio: 3.0–4.4 0 –
Diabetes mellitus 6 RR: 2.3
Rate ratio: 1.5–3.1
0 –
Chronic heart disease 3 Rate ratio: 3.8–5.1 0 –
Invasive pneumococcal disease
Chronic respiratory diseases 9** OR: 2.1–16.8
Rate ratio: 2.5–7.7
4†† OR: 1.3–4.7
Current smoking status 5 OR: 2.2
RR: 2.7
Rate ratio: 3.6–4.3
1 OR: 1.1
Diabetes mellitus 10 OR: 1.4–4.6
Rate ratio: 1.5–3.9
2 OR: 1.5–1.7
Chronic heart disease 5 OR: 3.0–6.9
Rate ratio: 2.9–3.9
4 OR: 1.7–9.9
*For studies that only reported data separately for each cohort, all cohorts were included; for studies that reported data for the overall study population, the summary data were used.
†Risk in individuals with factor versus risk in those without risk factor; ranges are based on the lowest and highest values from the publications evaluated using the risk terminology
(eg, relative risk or risk ratio) as stated in the original publications.
‡Comprising the following diseases (number of cohorts): asthma (3), bronchitis (0), COPD (1), lung disease (not specified; 4).
§Comprising the following diseases (number of cohorts): asthma (3), bronchitis (1), COPD (5), lung disease (not specified; 6).
¶Comprising the following diseases (number of cohorts): asthma (3), lung disease (not specified; 3).
**Comprising the following diseases (number of cohorts): asthma (4), lung disease (not specified; 5).
††Comprising the following diseases (number of cohorts): asthma (2), COPD (2).
HR, hazard ratio; OR, odds ratio; RR, relative risk.
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Smoking status
Smoking has also been identiﬁed as a risk factor for CAP (ORs
for current smoking: 1.0–2.3) with the risk varying according to
smoking history (table 1; see online supplementary table
S2).7 15 16 18 19 21 22 24 29 The effect of smoking on the risk of
CAP has been explored in a case–control study.16 Compared
with individuals who had never smoked, current smokers and
ex-smokers were found to have a higher risk of CAP (OR: 1.34
and 1.37, respectively), with smoking conﬁrmed as an inde-
pendent risk factor in a multivariate analysis. This risk increased
with the number of pack-years (OR vs 0 pack-years: 1.46 for
>150 pack-years and 1.01 for ≤150 pack-years). Among the
ex-smokers, those who had stopped smoking >4 years ago had
a signiﬁcantly reduced risk of CAP than those who had stopped
smoking <1 year ago (OR: 0.39). Individuals aged >65 years
who had never smoked but were exposed to passive smoking
were also at signiﬁcantly increased risk of CAP (OR adjusted for
age and sex: 1.56).16 Similarly, in a separate study, individuals
aged ≥65 years who were exposed to passive smoke at home
had an increased risk of CAP (relative risk (RR): 1.48 vs those
not exposed to passive smoke).29
In another study in individuals aged ≥65 years, current
smokers had a higher risk of CAP than ex-smokers irrespective
of age (OR for all ages: 1.8 vs 1.3).19 Based on the population
attributable fraction, which is a measure of the proportion of
cases attributed to a particular risk factor, Jackson et al19
calculated that 2.4% of CAP cases are due to current smoking,
increasing to 5.5% of cases in those with no cardiopulmonary
disease. In contrast, in a study involving individuals with
COPD, current smoking was not found to affect CAP incidence,
which the authors attributed to inaccurate recording of current
smoking status (20% of individuals were reported to have never
smoked), other causes of COPD such as occupational exposures,
or individuals with severe COPD ceasing to smoke.21
The effect of smoking status on IPD incidence is variable,7 25 26 30
which may reﬂect the variable prevalence of smoking within
different populations.26 In US adults with chronic medical
conditions, Shea et al7 calculated rate ratios of 3.6 in smokers aged
18–49 years to 4.3 in those aged 50–64 years.
In another US study, the risk of bacteraemic pneumococcal
pneumonia in adults was signiﬁcantly higher in current smokers
than in those who have never smoked or are not currently
smoking (multivariate adjusted OR: 2.2).25 Smokers were also
shown to be 3.7 times more likely to develop pneumococcal
bacteraemic pneumonia than non-smokers in an Australian
study.30 In contrast, former or current smoking was not asso-
ciated with IPD in Navajo adults in whom the prevalence of
smoking was low.26
Diabetes mellitus
Patients with diabetes have an increased risk of up to 1.4 for
CAP and ranging from 1.4 to 4.6 for IPD (ORs; table 1; see
online supplementary table S3).7 8 12–16 19 21 23–26 30–34
Analysis of long-term UK data suggests that the risk of lobar
pneumonia, pneumococcal pneumonia, septicaemia and menin-
gitis in patients hospitalised with diabetes declined little
between 1963 and 2011. However, a decreased risk of pneumo-
coccal disease was observed in individuals aged <60 years in
recent years (2007–11), which coincided with the introduction
of pneumococcal conjugate vaccines (PCVs) in childhood vac-
cination programmes in 2006.14
Diabetes has the greatest impact on the risk of IPD and CAP
in individuals aged <64 years and especially in those aged
≤40 years or without other comorbidities.12 32 In a Danish
case–control study, individuals <40 years of age with diabetes
were found to have a threefold higher risk of hospitalisation due
to pneumonia than individuals without diabetes of a similar age,
with the RR decreasing in older age groups. The risk of
pneumonia-related hospitalisation associated with diabetes was
also greater in those with no other comorbidities, and in those
with a longer duration of diabetes and/or poor glycaemic
control (based on A1C levels).32 Similarly, in a US study, increas-
ing levels of A1C were associated with an increasing risk of CAP
in patients with diabetes.31 It has been suggested that the
increased risk of pneumococcal infection in patients with dia-
betes results from the harmful effects of hyperglycaemia on
immune and/or pulmonary function.35 36
Chronic heart disease
Patients with CHD (including congestive heart failure (CHF)
and cardiovascular and valve diseases) have up to a 3.3-fold
increased risk (OR) of CAP and up to a 9.9-fold increased risk
(OR) of IPD compared with those without CHD, with risk
varying according to the condition and age of the individual
(table 1; see online supplementary table S4).7 8 10–13 15 16
18 19 21 22 24 26 In individuals living in the US and aged
≥65 years, heart disease was identiﬁed as an independent risk
factor for CAP with 16% of cases attributed to heart disease.
The risk of CAP was greater in those with heart disease of a
greater severity: individuals with non-CHF heart disease had
only a modest increase in the risk of CAP (OR: 1.2 vs those
with no heart disease), whereas those with mild or severe CHF
had a twofold and threefold increased risk, respectively.19
These ﬁndings are supported by data from a large population-
based study of 67 000 patients with pneumonia, in which
patients with CHF had an almost twofold increased risk of hos-
pitalisation as a result of pneumonia relative to those without
CHF.10 The risk of pneumonia was affected by the underlying
condition associated with the heart failure and the medical treat-
ment administered. Patients with cardiomyopathy, as well as
those treated with loop diuretics, were found to be especially at
risk of hospitalised CAP. Similarly, in a separate study, treatment
of heart failure with amiodarone was found to be an independ-
ent risk factor for CAP.16
The incidence of CAP and IPD in US individuals has also
been found to increase with increasing age, although the rate
ratios between patients with CHD and healthy individuals was
higher in the 18–49-year age group than in the older age groups
due to the low background incidence in the younger age group.7
This reﬂects the fact that increasing age is itself a risk factor for
pneumococcal disease and as such has a diluting effect on the
increased risk associated with comorbidities in the older age
groups.
Multiple risk factors
Multiple risk factors for pneumococcal disease are frequently
observed in individuals >65 years of age, with more than 60%
having two or more underlying medical conditions.37–39
Multiple conditions have been shown to have a cumulative
effect on the risk of CAP/IPD, as well as on the mortality asso-
ciated with these diseases.7 9 40 The risk of pneumococcal
disease (all-cause pneumonia, pneumococcal pneumonia and
IPD) increases as the number of risk factors increases in differ-
ent age groups (18–49, 50–64 and ≥65 years).7 Rates are par-
ticularly high in those with three or more conditions (eg, RR
for pneumococcal pneumonia relative to healthy individuals:
16.5, 12.8 and 9.2, respectively).
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CONSEQUENCES OF CHRONIC DISEASES ON
PNEUMOCOCCAL DISEASE OUTCOMES
The presence of chronic diseases not only increases the risk of an
individual acquiring a pneumococcal disease, but can also
adversely affect the severity and outcome of that disease. Both
COPD and diabetes have been shown to be signiﬁcant predictors
of hospitalisation in patients with CAP.41 Furthermore, the risk of
respiratory and cardiac complications—both of which are asso-
ciated with increased mortality—is greater in individuals with
chronic lung and/or heart diseases than in other individuals.42 43
In adults hospitalised due to IPD, the following independent
risk factors for respiratory failure were identiﬁed: age >50 years
(OR 1.63), chronic lung disease (OR 1.54), CHD (OR 1.49),
and infection caused by serotype 3 (OR 1.97), serotype 19A
(OR 2.34) and serotype 19F (OR 3.55).42
Cardiac complications have also been found to affect more
than one-quarter of individuals hospitalised as a result of CAP
and were associated with a 60% increased risk of 30-day mortal-
ity.43 An increased risk of cardiac complications was observed in
individuals with increased cardiovascular risk, such as those
with preexisting heart failure (OR: 4.3), cardiac arrhythmias
(OR: 1.8), coronary artery disease (OR: 1.5) or arterial hyper-
tension (OR: 1.5).
Patients with chronic comorbidities are at increased risk of
death from CAP or IPD over both the short term (eg, 30 days)
and long term (1 year).44–48 Adamuz et al investigated the inci-
dence, causes and risk factors associated with 1-year mortality in
patients with CAP after hospital discharge. They reported a 7%
1-year mortality rate following discharge from hospital, with
most patients dying as a result of infectious diseases (mostly
pneumonia) or acute cardiovascular events.45 Independent risk
factors for 1-year mortality in these patients were comorbidity
(including COPD and diabetes mellitus), rehospitalisation within
30 days of hospital discharge, and nursing home residence.45
The risk of mortality from CAP or IPD in patients with COPD
varies according to the study.49 COPD (deﬁned using spirometry)
was found to be an independent risk factor for 30-day mortality
in Spanish patients with CAP,48 whereas other studies in patients
with CAP or pneumococcal bacteraemic pneumonia have not
demonstrated increased 30-day mortality in patients with COPD
compared with those without COPD.44 46 50
This variability may reﬂect differences in the deﬁnitions used
for COPD, as not all of these studies used spirometric measure-
ments to diagnose COPD.44 46 However, Liapikou et al50
observed a similar mortality rate in patients with spirometry-
conﬁrmed COPD to that in patients without COPD. Although
patients with COPD presented with more severe respiratory
failure (arterial oxygen tension/inspiratory oxygen fraction) and
more severe pneumonia (pneumonia severity index), they had
less multilobar inﬁltration and fewer pulmonary complications
compared with those without COPD.50 This reduction in pul-
monary complications has been attributed to the use of inhaled
corticosteroids, possibly reducing the inﬂammatory response in
the lung in these patients. This is supported by ﬁndings that
prior treatment with inhaled corticosteroids in patients with
chronic respiratory disorders who develop pneumonia is asso-
ciated with a lower incidence of parapneumonic effusion.51
Mortality risk appears to increase in those with COPD and
prior cardiovascular disease; older patients with COPD and
prior cardiovascular disease have been reported to have a signiﬁ-
cantly increased 12-month mortality risk (adjusted OR: 1.34)
compared with those without cardiovascular disease.52
Smoking has been identiﬁed as an independent risk factor for
mortality associated with pneumococcal bacteraemic pneumonia
and CAP. In patients with pneumococcal bacteraemic pneumo-
nia, smoking was attributed to 14.9% of the 30-day mortality,
based on the population attributable proportion.44 In a separate
study of patients hospitalised with CAP, current smokers had a
ﬁvefold increased risk of 30-day mortality from pneumococcal
CAP compared with non-smokers and ex-smokers, and current
smoking status remained an independent risk factor for
pneumococcal CAP compared with non-smoking status alone
and ex-smoking status alone (OR: 4.0 and 3.9, respectively).53
Diabetes is an independent risk factor (OR: 1.67) for the devel-
opment of bacteraemia in patients with pneumococcal pneumonia,
which in turn is associated with signiﬁcantly increased mortality
versus non-bacteraemic pneumonia (OR: 2.57).54
Patients with CHF are at increased risk of a complicated
episode of CAP (based on a combined endpoint of 30-day
home-treated complications, hospitalisation or all-cause mortal-
ity; OR: 3.13),55 and at increased risk of 30-day mortality.46 47
Analysis of data from the German Competence Network for
Community-Acquired Pneumonia (CAPNETZ) study found that
CHF and CHD were risk factors for 30-day mortality in
patients with CAP in a univariate analysis (ORs: 4.91 and 2.76,
respectively) but not in a multivariate analysis.46 In a separate
study involving Danish patients hospitalised for pneumonia,
those with CHF had an increased 30-day mortality rate versus
other patients (adjusted mortality rate ratio (MRR): 1.40).47
Mortality increased with increasing severity of CHF before
admission, based on medication regimen. Patients receiving
loop-diuretics and spironolactone (drugs used for CHF
New York Heart Association Functional Classiﬁcation III–IV)
were at a particularly high risk for death due to pneumonia
(MRR: 1.72), whereas those using a thiazide as the sole diuretic
had a mortality rate similar to that of other patients with pneu-
monia (MRR: 1.09).47
A hospital-based epidemiological study of IPD in adults in
Belgium also demonstrated a signiﬁcantly higher case fatality
rate during hospitalisation in those with heart failure compared
with those without heart failure (OR: 1.70).56
CAP may also worsen a patient’s underlying condition, as
reported in a US survey of adults aged ≥50 years with CAP, in
which ≥20% of individuals experienced a worsening of COPD,
asthma or hypertension.57 This deterioration in the patient’s
underlying condition may in turn adversely affect the patient’s
prognosis. For example, previously diagnosed pneumonia in
patients hospitalised for COPD exacerbation has been shown to
increase inpatient mortality.58 In another study, patients with
COPD exacerbations and pneumonia had poorer outcomes,
including inpatient and 90-day mortality, compared with those
with non-pneumonic COPD exacerbations.59
Patients have been reported to have ongoing subclinical
inﬂammation following recovery from pneumonia, and this has
been associated with an increased risk of death due to cardiovas-
cular disease in these individuals.60 Worsening prior cardiovas-
cular disease in patients with COPD has also been attributed as
a cause of increased long-term mortality following pneumo-
nia.52 Similarly, deterioration of underlying cardiovascular
disease has been associated with increased 1-year mortality fol-
lowing pneumonia in patients with diabetes mellitus versus
those without diabetes.61
The mechanisms linking pneumonia to cardiac events such as
myocardial infarction, arrhythmias and CHD are multifactorial.
They include thrombogenesis/rupture of vulnerable plaques, and
myocardial stress and suppression resulting from increased myo-
cardial oxygen demand, lowered blood oxygen levels, depressed
ventricular function and elevated levels of cytokines.60 62 63
Torres A, et al. Thorax 2015;70:984–989. doi:10.1136/thoraxjnl-2015-206780 987
Review
group.bmj.com on November 8, 2016 - Published by http://thorax.bmj.com/Downloaded from 
ECONOMIC BURDEN OF PNEUMOCOCCAL DISEASE
Pneumococcal pneumonia results in a more severe disease
course requiring more medical resources than non-
pneumococcal pneumonia.64 Data from the CAPNETZ study
suggest that patients with pneumococcal pneumonia are more
likely to be hospitalised, to have higher pneumonia severity
(Confusion, Urea, Respiratory Rate and Blood Pressure (CURB))
score values on admission and pleural effusion, and to require
oxygen insufﬂation than those with non-pneumococcal pneumo-
nia.64 CAP, and speciﬁcally pneumococcal pneumonia, therefore
imposes a signiﬁcant economic burden.65
Economic studies conducted in the US and in Eastern Europe
suggest that healthcare costs for CAP requiring hospitalisation
are high and increase with increasing risk level of CAP.66–68
Major determinants of total healthcare costs are admission to an
intensive care unit69 70 and length of hospital stay,69 71 which is
in turn dependent on the presence of speciﬁc comorbidities, the
development of complications and the severity of the
pneumonia.
Bacteraemia and CHF have been found to be positive predic-
tors of length of hospital stay in adults with pneumococcal
pneumonia.70 Independent predictors of longer length of hos-
pital stay in patients with CAP also include chronic respiratory
disease, diabetes, multilobar CAP, as well as older age
(≥70 years), pneumonia severity index class on admission, and
development of CAP-associated complications.72
In addition to inpatient care, long duration of antibiotic
therapy and a large number of visits at different healthcare
levels (primary care, hospital outpatient and emergency depart-
ments) have been shown to contribute to the high cost of treat-
ing CAP.73
It has been suggested that the higher costs of treating those
with comorbidities and CAP than those without comorbidities
are due to exacerbation of the underlying conditions, leading to
additional costs.74 In line with this, the proportion of
CAP-related costs has been found to decrease with increasing
risk for CAP, suggesting that a greater proportion of healthcare
costs are associated with treating underlying conditions in high-
risk versus low-risk patients.66 Furthermore, a 20% increase in
hospitalisation for pneumonia observed among US individuals
aged ≥65 years from 1988–1990 to 2000–2002 has, in part,
been attributed to an increase in comorbidities in these indivi-
duals.75 Complications (especially infectious diseases), hypoal-
buminaemia and previous hospital admission have also been
linked with the high costs associated with hospitalised patients
with CAP.71
Pneumococcal disease (CAP/IPD) signiﬁcantly affects patients’
quality of life, causing extra days off work, more frequent visits
to primary care providers, and requiring additional medication
and assistance from caregivers.1 57 74 Patients with a serious
chronic condition who are hospitalised for CAP are also more
likely to leave their job.74 The US survey (mentioned above)
suggested that cough and weakness associated with CAP
adversely affects an individual’s capacity to carry out daily activ-
ities, such as housework and visiting places/other individuals.57
CONCLUSIONS
Adults with chronic conditions and other risk factors such as
COPD, asthma, smoking, diabetes mellitus and CHD are not
only at increased risk of pneumococcal infections, but also at
increased risk of complications/mortality if they have pneumo-
coccal disease. This highlights the need for timely pneumococcal
vaccination in these patients.
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